secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001193125-26-160347
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences expands board to ten, appoints Habib J. Dable as Class II director
--------------------------------------------------------------------------------

- Board increased from nine to ten members; Dable appointed effective April 16, 2026, with term expiring at 2026 annual meeting.
- Dable previously President & CEO of Acceleron Pharma (acquired by Merck in 2021) and advisor at RA Capital since April 2022.
- Received option to purchase 44,400 shares vesting equally over 36 months; cash compensation per Non-Employee Director Program.
- Board determined Dable is independent under Nasdaq listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526160347/0001193125-26-160347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526160347/d17006d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-160347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer